There have been calls for caution when it comes to the use of Pfizer’s respiratory syncytial virus (RSV) vaccine in pregnant women, ahead of an FDA advisory committee meet
Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibro
Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseas
Johnson & Johnson’s appetite for building a new generation of CAR-T therapies for cancer shows no sign of being sated – its Janssen Biotech unit has just paid $245 mil
AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US.